Mechanistic and Pharmacokinetic Studies of Classical Chinese Formula Xiao Chai Hu Tang Against Irinotecan-Induced Gut Toxicities

中药方剂小柴胡汤抗伊立替康肠道毒性的机制和药代动力学研究

基本信息

  • 批准号:
    10463682
  • 负责人:
  • 金额:
    $ 19.3万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-11 至 2025-06-30
  • 项目状态:
    未结题

项目摘要

Abstract Irinotecan, a prodrug of SN-38, is used to treat many types of metastatic and drug-resistant cancers, and often represents the therapy of the last resort. Unfortunately, a large percentage (up to 40%) of these patients will experience serious (Grade 2) and severe (Grade 3-4) delayed-onset diarrhea (SDOD), which really downgrade patient’s quality of life. SDOD may lead to prolonged hospitalization and even death in some instances. The long-term goal of our research is to develop experimental therapeutics and/or nutritional supplemental approach to reduce SDOD, so patients can sustain their chemotherapy. Our recent studies have shown that inactivation of intestinal UDP-glucuronosyltransferases (UGTs) by SN-38 is a new mechanism by which SN-38 causes SDOD, and that a Traditional Chinese Medicine, Xiao-Chai-Hu-Tang (XCHT), could attenuate the inactivation of intestinal UGTs in mice. Therefore, the central hypothesis of this current proposal is Therefore, we hypothesize that XCHT will prevent or reduce irinotecan-induced SDOD by attenuating the decline in UGT activities, reducing gut SN-38 exposure, and promoting the recovery of gut UGT activities. We plan to test this hypothesis using four Specific Aims: (1) perform phytochemical, biopharmaceutical and pharmacokinetic characterization of XCHT to enable quality control, systemic and intestinal drug exposure determinations, and to provide bioanalytical methods and pharmacokinetic parameters needed for a clinical study and PK/PD modeling; (2) validate plasma raloxifene-4′-glucuronide levels as a probe to changes in intestinal Ugt/UGT activity; (3) Perform mouse “co- trial” studies to support human mechanistic trials and to determine the mechanisms of action of XCHT against irinotecan-induced SDOD using both in vitro and in vivo models; and (4) Conduct a mechanistic clinical trial using a randomized double-blind design with a safety “Run-In” to determine if XCHT can attenuate human intestinal UGT decrease and reduce incidence of Grade 3 or higher diarrhea caused by irinotecan chemotherapy. Aside from these primary outcomes, we will also determine if levels of Ral-4’-G, a probe of intestinal UGT activities is (negatively) correlated with systemic levels of inflammatory cytokines. Success gained through this research will provide a new mechanism by which we can target to treat SDOD caused by irinotecan chemotherapy.
摘要 伊立替康是SN-38的前药,用于治疗多种类型的转移性和耐药癌症,通常 代表了最后一招的疗法。不幸的是,这些患者中有很大一部分(高达40%)将 经历严重(2级)和严重(3-4级)延迟性腹泻(SDOD),这确实降低了级别 患者的生活质量。在某些情况下,SDOD可能会导致延长住院时间,甚至死亡。这个 我们研究的长期目标是开发实验性疗法和/或营养补充方法。 以减少SDOD,这样患者就可以继续进行化疗。我们最近的研究表明,灭活 SN-38对肠道UDP-葡萄糖醛酸基转移酶(UGTS)的作用是SN-38致病的新机制 而中药小柴胡汤(XCHT)可减轻小鼠脑组织中HSP70的失活 小鼠肠道UGT。因此,当前提案的中心假设是,因此,我们假设 XCHT将通过减弱UGT活性的下降,减少伊立替康诱导的SDOD,从而预防或减少伊立替康诱导的SDOD 肠道SN-38暴露,促进肠道UGT活性恢复。我们计划用四个实验来检验这一假设 具体目标:(1)进行XCHT的植物化学、生物制药和药代动力学表征 支持质量控制、全身和肠道药物暴露测定,并提供生物分析 临床研究和PK/PD模型所需的方法和药代动力学参数;(2)验证血浆 以雷洛昔芬-4‘-葡萄糖醛酸苷水平作为肠道UGT/UGT活性变化的探针; 支持人体机械性试验并确定XCHT抗肿瘤作用机制的研究 使用体外和体内模型进行伊立替康诱导的SDOD;以及(4)使用 一项安全“磨合”的随机双盲设计,以确定XCHT是否可以弱化人体肠道 UGT减少和降低伊立替康化疗引起的3级或更高程度腹泻的发生率。搁置一边 根据这些初步结果,我们还将确定肠道UGT活动的探针al-4‘-G的水平是否 与全身炎症细胞因子水平呈负相关。通过这项研究取得的成功将 为我们靶向治疗伊立替康化疗所致的SDOD提供了新的机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MING HU其他文献

MING HU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MING HU', 18)}}的其他基金

Elucidating High Oral Fluid Exposure Mechanisms of Buprenorphine to Reduce Dental Caries
阐明丁丙诺啡的高口腔液暴露机制以减少龋齿
  • 批准号:
    10765181
  • 财政年份:
    2023
  • 资助金额:
    $ 19.3万
  • 项目类别:
Development of Drug Detoxifying Bacteria for Chemotherapy Induced Gut Injury
开发用于化疗引起的肠道损伤的药物解毒细菌
  • 批准号:
    10560782
  • 财政年份:
    2021
  • 资助金额:
    $ 19.3万
  • 项目类别:
Development of Drug Detoxifying Bacteria for Chemotherapy Induced Gut Injury
开发用于化疗引起的肠道损伤的药物解毒细菌
  • 批准号:
    10252721
  • 财政年份:
    2021
  • 资助金额:
    $ 19.3万
  • 项目类别:
Mechanistic and Pharmacokinetic Studies of Classical Chinese Formula Xiao Chai Hu Tang Against Irinotecan-Induced Gut Toxicities
中药方剂小柴胡汤抗伊立替康肠道毒性的机制和药代动力学研究
  • 批准号:
    10262912
  • 财政年份:
    2020
  • 资助金额:
    $ 19.3万
  • 项目类别:
Mechanistic and Pharmacokinetic Studies of Classical Chinese Formula Xiao Chai Hu Tang Against Irinotecan-Induced Gut Toxicities
中药方剂小柴胡汤抗伊立替康肠道毒性的机制和药代动力学研究
  • 批准号:
    10686830
  • 财政年份:
    2020
  • 资助金额:
    $ 19.3万
  • 项目类别:
Inhibition of Oral Tumorigenesis by Antitumor B
抗肿瘤 B 抑制口腔肿瘤发生
  • 批准号:
    10516360
  • 财政年份:
    2016
  • 资助金额:
    $ 19.3万
  • 项目类别:
Inhibition of Oral Tumorigenesis by Antitumor B
抗肿瘤 B 抑制口腔肿瘤发生
  • 批准号:
    10170283
  • 财政年份:
    2016
  • 资助金额:
    $ 19.3万
  • 项目类别:
Disposition of Flavonoids via Glucuronidation, Critical Role of Efflux Transporte
通过葡萄糖醛酸化处理黄酮类化合物,外排转运的关键作用
  • 批准号:
    8870372
  • 财政年份:
    2006
  • 资助金额:
    $ 19.3万
  • 项目类别:
Disposition of Flavonoids via Metabolic Interplay
通过代谢相互作用处理黄酮类化合物
  • 批准号:
    7784367
  • 财政年份:
    2006
  • 资助金额:
    $ 19.3万
  • 项目类别:
Disposition of Flavonoids via Glucuronidation, Critical Role of Efflux Transporte
通过葡萄糖醛酸化处理黄酮类化合物,外排转运的关键作用
  • 批准号:
    9267482
  • 财政年份:
    2006
  • 资助金额:
    $ 19.3万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了